Vectura's Archives - World Asthma Foundation

August 5, 2011

Sandoz Negotiates Expanded RoW Rights to Vectura’s Asthma/COPD Drug VR315 – Genetic Engineering News

Sandoz Negotiates Expanded RoW Rights to Vectura's Asthma/COPD Drug VR315
Genetic Engineering News
The Novartis generics business, Sandoz, negotiated expanded, rest-of-world (excluding the US) rights to Vectura's VR315 candidate combination therapy for asthma/COPD. Sandoz already holds European rights to the dry powder inhaler product. …
Vectura Extends Novartis Deal For VR315 Lung DrugFox Business
VECTURA GROUP PLC : VR315 RoW License Agreement4-traders (press release)
Vectura signs up Sandoz for asthma drug in RoW; good results for ALK Abello …The Pharma Letter
Stockopedia
all 9 news articles »

View full post on asthma – Google News

February 17, 2011

Cost savings boost Vectura’s cash resources – Reuters

Cost savings boost Vectura's cash resources
Reuters
L) said cost savings had put it in a stronger position than expected as it awaits trial results and European approvals for its medicine to treat asthma. The British company, which has developed what is potentially a generic rival to GlaxoSmithKline's …

and more »

View full post on asthma – Google News